Abstract: The present disclosure provides methods, drug combinations and kits for treating, ameliorating, reversing and/or preventing a Helicobacter pylori (H. pylori) infection in a patient in need thereof.

Abstract: The present application relates to a pharmaceutical composition comprising sulbactam or a pharmaceutically acceptable salt thereof, avibactam or a pharmaceutically acceptable salt thereof, and optionally a pharmaceutically acceptable carrier, wherein unit dose ratio of said sulbactam or the pharmaceutically acceptable salt thereof and said avibactam or the pharmaceutically acceptable salt thereof is about 8:1 to about 4:1, unit dose of said sulbactam or the pharmaceutically acceptable salt thereof is about 1 g-4 g, and unit dose of said avibactam or the pharmaceutically acceptable salt thereof is about 0.125 g-1 g. The present application also relates to methods of treating bacterial infections using said pharmaceutical composition.

Abstract: A layout method of large-flux algae control wells based on a sluice-pump hub area includes: defining positions of a sluice-pump hub and a river diversion channel as a sluice-pump hub area, arranging at least two sets of pumping station units at the water outlet end of the river diversion channel, using a water flow model to guide streamline and flow velocity distribution of water flow in the river diversion channel, and determining whether it is necessary to adopt rectification measures based on water flow streamline and flow velocity distribution; and obtaining hydraulic characteristic values of the pumping station units, determining whether the currently arranged algae control wells and the adopted rectifying measures simultaneously meet the algae control requirements and subsequent running requirements of the pumping station units based on the hydraulic characteristic values.

Abstract: The present invention provides an application of a rifamycin-quinolizidone conjugate molecule shown in formula I and pharmaceutically acceptable salt thereof in preparation of a drug for treating or preventing infections caused by methicillin-resistant, quinolone-resistant, and methicillin and quinolone multidrug resistant Staphylococcus aureus. The rifamycin-quinolizidone conjugate molecule and pharmaceutically acceptable salt thereof provided by the present invention can effectively treat or prevent bacterial infections and diseases caused by methicillin-resistant, quinolone-resistant, and methicillin and quinolone multidrug resistant Staphylococcus aureus, and can reduce spontaneous resistance frequency as compared with a drug combination of rifamycin and quinolones.

Abstract: The present invention provides a solid dispersion of a rifamycin-nitroimidazole coupling molecule, comprising a rifamycin-nitroimidazole coupling molecule of a structure shown in formula I, a polymer carrier, functional excipient and a solvent. The polymer carrier is selected from one or a combination of more of PVP K30, PVP-VA64, HPC-L, HPMC E3, Soluplus and polymethacrylate. The functional excipient comprise one or a combination of more of sodium lauryl sulfate, meglumine, VE-TPGS and Tween 80. The solid dispersion of the rifamycin-nitroimidazole coupling molecule of the present invention can be used as a formulation of a drug for treating microbial infection.

Abstract: Novel iron chelating group conjugated penam derivatives described herein show antibacterial activity, and could be used as antibacterial agents or beta-lactamase inhibitors (BLIs) which are of value for application in combination with other antibacterial agents.

Abstract: The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.

Abstract: Novel iron chelating group conjugated penam derivatives described herein show antibacterial activity, and could be used as antibacterial agents or beta-lactamase inhibitors (BLIs) which are of value for application in combination with other antibacterial agents.

Abstract: The present invention provides a use of a rifamycin-nitroimidazole coupling molecule, or a stereoisomer, hydrate, deuterium-substituted form, ester, solvate, crystal form, metabolite, pharmaceutically acceptable salt or prodrug thereof in resisting nontuberculous mycobacteria. The rifamycin-nitroimidazole coupling molecule has a structure shown in formula (I) below. The rifamycin-nitroimidazole coupling molecule, or the stereoisomer, hydrate, deuterium-substituted form, ester, solvate, crystal form, metabolite, pharmaceutically acceptable salt or prodrug thereof may effectively against nontuberculous mycobacteria, and then may be used for treating infection caused by nontuberculous mycobacteria.

Abstract: The present invention provides a use of a rifamycin-quinolizidone coupling molecule, or a stereoisomer, hydrate, deuterium-substituted form, ester, solvate, crystal form, metabolite, pharmaceutically acceptable salt or prodrug thereof in resisting nontuberculous mycobacteria. The rifamycin-quinolizidone coupling molecule has a structure shown in formula (I) The rifamycin-quinolizidone coupling molecule, or the stereoisomer, hydrate, deuterium, ester, solvate, crystal form, metabolite, pharmaceutically acceptable salt or prodrug thereof may effectively against nontuberculous mycobacteria, and then may be used for treating infection caused by human nontuberculous mycobacteria.

Abstract: A method of inhibiting anaerobic bacteria includes administering to a patient in need thereof a rifamycin-nitroimidazole conjugate molecule shown in formula I. The rifamycin-nitroimidazole conjugate molecule shown in formula I of the present invention has broad-spectrum antibacterial activity against anaerobic bacteria, including activity against most pathogenic bacteria associated with bacterial vaginosis, in vitro antibacterial activity stronger than that of drugs against bacterial vaginosis such as metronidazole and clindamycin, and potential use in prevention and treatment of bacterial vaginosis or other related diseases caused by anaerobic bacteria.

Abstract: A method of inhibiting gastrointestinal ammonia-producing bacteria includes administering to a patient in need thereof a rifamycin-quinolizidone dual-action molecule shown in formula I. The rifamycin-quinolizidone dual-action molecule shown in formula I of present invention has an antibacterial spectrum similar to that of rifaximin, stronger antibacterial activity against the gastrointestinal common ammonia-producing bacteria, low frequency for resistance development, and potential use in prevention and treatment of hepatic encephalopathy and related bacterial infections.

Abstract: The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.

Abstract: The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.

Abstract: The present invention relates to compounds of formula (I) including any stereochemically isomeric form thereof, or pharmaceutically acceptable salts thereof, for the treatment of tuberculosis.

Abstract: Provide herein is an antibacterial pharmaceutical combination for treating Gram negative bacterial infections, including a compound TNP-2092 and a cell membrane permeabilizer. Also provided herein is a method for treating Gram-negative bacteria infections in a subject, which includes administrating to the subject the antibacterial pharmaceutical combination.

Abstract: The present invention relates to novel nitroimidazooxazines, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments.

Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments. A general representation of the 2-(heteroaryl)amino-riminophenazines is shown below.

Abstract: The present invention relates to riminophenazines having heteroaromatic substitutions, including those with 2-heteroaryl-amino substituents, to their preparation, and to their use as drugs for treating Mycobacterium tuberculosis and other microbial infections, either alone or in combination with other anti-infective treatments. A general representation of the 2-(heteroaryl)amino-riminophenazines is shown below.

Abstract: The current invention pertains to nitroimidazooxazine and nitroimidazooxazole analogues, their methods of preparation, and uses of the compounds as treatment for Mycobacterium tuberculosis, for use as anti-tubercular drugs, for use as anti-protozoal agents with unexpectedly high potency against Trypanosoma cruzi or Leishmania donovani, and for the treatment of other microbial infections.